KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Consolidated Net Income (2016 - 2025)

Teva Pharmaceutical Industries' Consolidated Net Income history spans 10 years, with the latest figure at $470.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Consolidated Net Income rose 270.91% year-over-year to $470.0 million, compared with a TTM value of $1.4 billion through Dec 2025, up 171.62%, and an annual FY2025 reading of $1.4 billion, up 171.58% over the prior year.
  • Consolidated Net Income for Q4 2025 was $470.0 million at Teva Pharmaceutical Industries, up from $432.0 million in the prior quarter.
  • The five-year high for Consolidated Net Income was $470.0 million in Q4 2025, with the low at -$1.3 billion in Q4 2022.
  • Average Consolidated Net Income over 5 years is -$162.4 million, with a median of -$43.5 million recorded in 2021.
  • Year-over-year, Consolidated Net Income soared 296.23% in 2021 and then plummeted 1286.59% in 2022.
  • Tracing TEVA's Consolidated Net Income over 5 years: stood at -$151.0 million in 2021, then crashed by 783.44% to -$1.3 billion in 2022, then surged by 134.93% to $466.0 million in 2023, then tumbled by 159.01% to -$275.0 million in 2024, then soared by 270.91% to $470.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Consolidated Net Income are $470.0 million (Q4 2025), $432.0 million (Q3 2025), and $281.0 million (Q2 2025).